Replies to post #133579 on Biotech Values

[DewDiligence]

Without biosimilar approval framework, patent exp. dates meaningless in many cases.

I do not understand what you mean. Companies are already inking FoB partnerships and have been meeting with the FDA to get guidance on FoB clinical-trial designs. The guidance documents that the FDA eventually publishes will codify and possibly expand on what the FDA is already telling companies during these meetings.